Baptist Health Lexington

James M Winkley, II

Principal Investigator

Emily Keefe

Want to join the trial?

Choose a location to contact our Clinical Trial Coordinator and to discuss potential opportunities.

Email Coordinator


ALXN-MG-501: Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies

This is a long-term, multicenter, observational registry of participants with generalized myasthenia gravis (gMG) who are treated with Alexion complement C5 inhibition therapies (C5IT) prior to enrollment.

Learn more at
Eligibility Criteria


  • Participants with gMG who have received treatment with Alexion C5IT.
  • Capable of giving signed informed consent, which includes compliance with the protocol requirements and restrictions.
  • Participants must have myasthenia gravis historical data available to be enrolled in the Registry.


  1. Participants currently enrolled in an Alexion-sponsored interventional clinical study for treatment of gMG cannot be enrolled in the Alexion gMG Registry while enrolled/participating in the clinical study for gMG therapy.